Stifel Canada Issues Negative Estimate for TSE:CPH Earnings

Cipher Pharmaceuticals Inc. (TSE:CPH) (NASDAQ:CPHR) – Research analysts at Stifel Canada lowered their Q3 2024 earnings estimates for Cipher Pharmaceuticals in a report released on Tuesday, October 22nd. Stifel Canada analyst J. Keywood now forecasts that the company will earn $0.03 per share for the quarter, down from their prior estimate of $0.27. Stifel Canada has a “Strong-Buy” rating on the stock. The consensus estimate for Cipher Pharmaceuticals’ current full-year earnings is $1.65 per share. Stifel Canada also issued estimates for Cipher Pharmaceuticals’ FY2024 earnings at $0.72 EPS.

A number of other equities analysts have also recently weighed in on CPH. Stifel Nicolaus upped their price objective on shares of Cipher Pharmaceuticals from C$17.00 to C$19.00 in a research report on Thursday. Leede Financial cut shares of Cipher Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Friday, September 13th.

Cipher Pharmaceuticals Stock Performance

Shares of TSE CPH opened at C$16.15 on Friday. The company’s fifty day moving average price is C$16.40 and its 200 day moving average price is C$11.74. Cipher Pharmaceuticals has a 1 year low of C$4.30 and a 1 year high of C$19.69. The company has a market capitalization of C$413.28 million, a PE ratio of 13.02 and a beta of 1.20. The company has a debt-to-equity ratio of 0.33, a quick ratio of 2.67 and a current ratio of 11.18.

Cipher Pharmaceuticals (TSE:CPH) (NASDAQ:CPHR) last announced its quarterly earnings results on Thursday, August 8th. The company reported C$0.16 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of C$0.15 by C$0.01. Cipher Pharmaceuticals had a net margin of 102.01% and a return on equity of 28.43%. The firm had revenue of C$7.26 million for the quarter, compared to the consensus estimate of C$7.52 million.

Cipher Pharmaceuticals Company Profile

Cipher Pharmaceuticals Inc operates as a specialty pharmaceutical company in Canada. It offers Epuris (isotretinoin), an oral retinoid indicated for the treatment of severe nodular and/or inflammatory acne, acne conglobate, and recalcitrant acne; Actikerall, a topical solution indicated for the treatment of slightly palpable and/or moderately thick hyperkeratotic actinic keratosis (Grade I/II) of the face, forehead, and balding scalp; Ozanex for the topical treatment of impetigo; Vaniqa, a topical cream for the slowing of the growth of unwanted facial hair in women; Durela, an opioid analgesic for the management of moderate to moderately severe pain in adults; Brinavess for the rapid conversion of onset atrial fibriallation to sinus rhythm in adults; and Aggrastat, a reversible GP IIb/IIIa inhibitor for use in patients with Acute Coronary Syndrome.